IVOSIDENIB | IVOSIDENIB | ATC L01XX62
ANTINEOPLASTIC TARGETS MUTANT ISOCITRATE DEHYDROGENASE-1 (IDH1) IDH1 R132 INHIBITOR TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) | ORAL | Cmax 7.7 MICROMOLAR Tmax 3 HOUR VD 234 LITER PPB 94 PERCENT Cl 4.3 LITER / HOUR HT 93 HOUR SOLUBILITY PRACTICALLY INSOLUBLE IN AQUEOUS SOLUTIONS BETWEEN PH 1.2 AND 7.4 | ISOCITRATE DEHYDROGENASE-1 (IDH1) | Isocitrate dehydrogenase NADP cytoplasmic UNIPROT O75874 IDH1 more at DrugCentral | EMA ANSM (in French) Inxight Drugs Dailymed Drugs.com SIDER side effects Chemical Probes Portal ChEMBL BindingDB DrugBank |